Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
What you will and won't see at this year's UN General Assembly
23/09/2025
Canadian police arrest Khalistani activist on firearms charges
23/09/2025
Oil little changed as traders assess supply risks
23/09/2025
China floods the world with cheap exports after Trump's tariffs
23/09/2025
Asian markets edge higher after Wall Street rally
23/09/2025
IT stocks plummet as Trump increases H-1B visa costs
23/09/2025
